entertainment -WSS

entertainment

author：Wikipedia 2025-09-14 21:44:28 - browse：74927

A team of high-powered scientists and billionaire investors said Friday that they’re launching a biomedical institute in Cambridge’s Kendall Square with $500 million in private funding with the aim of shortening the path from research breakthroughs to life-saving medicines.

The institute, called Arena BioWorks, will put drug discovery and company creation under one roof, upending the traditional model where academic research and venture-backed drug development are separate.

Backed by deep-pocketed investors including Steve Pagliuca, the former co-chair of Bain Capital and Celtics co-owner, and high-tech mogul Michael Dell, Arena has already lured top scientists from academic labs with lucrative compensation packages, but so far has publicly named only a few.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： The world needs the new pandemic treaty

WSS

STAT Summit: Biotech founders on deal

Medical students need to learn the potent medicine of empathy

How climate

The Bio Revolution is changing business and society

Should insurance cover cosmetic surgery?

The HPV vaccine prevents cancer in men, too. Why do so few people get it?

knowledge

entertainment

explore

The cancer drug shortage isn’t new — and neither are the solutions

Decentralized clinical trials need collaboration to achieve wider use

Duchenne breakthrough therapy leaves behind pioneering families

Lawsuit challenges CMS nursing home minimum staffing rule

Cancer drug shortages should be causing more outrage

Bubonic plague hit France in 1720. Officials dithered. Sound familiar?

Medicare proposal to cover medical devices draws a mixed reaction

Why some fertility treatments produce more boy babies

Jerome Adams on the need for new antivirals for Covid

Unmasking the 'centricity' illusion in clinical trials

hotspot

First Opinion Podcast: Long Covid needs a new approach

CEOs share strategies for surviving biotech slump

Why we need mandatory labeling of GMO products

Ozempic cut risk of death in diabetes patients with chronic kidney disease

FDA warns J&J's Abiomed: We will regulate your software

Researchers explore possible ties between long Covid, menopause

knowledge

knowledge

explore

leisure time